These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33672357)

  • 21. The KRAS
    Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
    Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
    Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
    Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
    Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
    Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
    Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
    Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS
    Cai C; Yao S; Zou Y; Lu H; Chen X; Wang Y; Zheng K; Zhu F; Wang Y; Xiong H; Zhu J
    J Cell Mol Med; 2023 Jun; 27(12):1637-1652. PubMed ID: 37226642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling.
    Morel M; Long W
    Mol Oncol; 2024 Mar; 18(3):762-777. PubMed ID: 37983945
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
    Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
    Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
    J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
    Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
    Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
    [No Abstract]   [Full Text] [Related]  

  • 30. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
    Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.
    Riquelme E; Behrens C; Lin HY; Simon G; Papadimitrakopoulou V; Izzo J; Moran C; Kalhor N; Lee JJ; Minna JD; Wistuba II
    Cancer Res; 2016 Feb; 76(3):675-85. PubMed ID: 26676756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
    Liang SQ; Bührer ED; Berezowska S; Marti TM; Xu D; Froment L; Yang H; Hall SRR; Vassella E; Yang Z; Kocher GJ; Amrein MA; Riether C; Ochsenbein AF; Schmid RA; Peng RW
    Oncogene; 2019 Jan; 38(5):622-636. PubMed ID: 30171261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of real-life data from patients with NGS panel negative and
    Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ
    Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
    Tsai YS; Woodcock MG; Azam SH; Thorne LB; Kanchi KL; Parker JS; Vincent BG; Pecot CV
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 34990404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
    Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
    J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer.
    Alhayyani S; McLeod L; West AC; Balic JJ; Hodges C; Yu L; Smith JA; Prodanovic Z; Bozinovski S; Kumar B; Ruwanpura SM; Saad MI; Jenkins BJ
    Oncogene; 2022 Feb; 41(6):809-823. PubMed ID: 34857889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
    Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
    Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
    Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
    Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.